IRCT2012100611022N1 IRCT 2012-12-09 School of medicine- Tehran University of Medical Sciences Valsartan therapy in the treatment of thalassemia-induced dyspnea Comparison of the effects of valsartan versus sildenafil on pulmonary arterial pressure in thalassemia major and intermedia patients with pulmonary hypertension 2012-10-22 anticipated 100 Complete https://irct.ir/trial/11391 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A secondary Pulmonary hypertension due to the Thalassemia. Intervention 1: Group 2 patients (as Intervention) will take valsartan drug 20 mg PO daily for six months. Intervention 2: Group 1 patients (as control) will take Sildenafil drug 25 mg PO twice per day for six months.